Essa Pharma Stock Net Income
| EPIX Stock | USD 1.60 0.02 1.23% |
ESSA Pharma fundamentals help investors to digest information that contributes to ESSA Pharma's financial success or failures. It also enables traders to predict the movement of ESSA Stock. The fundamental analysis module provides a way to measure ESSA Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ESSA Pharma stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -25.7 M | -27 M | |
| Net Loss | -31.6 M | -30 M | |
| Net Loss | -25.7 M | -27 M | |
| Net Loss | (2.38) | (2.50) | |
| Net Income Per E B T | 1.15 | 1.10 |
ESSA | Net Income |
ESSA Pharma Company Net Income Analysis
ESSA Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current ESSA Pharma Net Income | (28.54 M) |
Most of ESSA Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ESSA Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ESSA Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ESSA Pharma is extremely important. It helps to project a fair market value of ESSA Stock properly, considering its historical fundamentals such as Net Income. Since ESSA Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ESSA Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ESSA Pharma's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ESSA Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ESSA Pharma reported net income of (28.54 Million). This is 108.36% lower than that of the Biotechnology sector and 140.75% lower than that of the Health Care industry. The net income for all United States stocks is 105.0% higher than that of the company.
ESSA Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ESSA Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ESSA Pharma could also be used in its relative valuation, which is a method of valuing ESSA Pharma by comparing valuation metrics of similar companies.ESSA Pharma is currently under evaluation in net income category among its peers.
ESSA Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of ESSA Pharma from analyzing ESSA Pharma's financial statements. These drivers represent accounts that assess ESSA Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ESSA Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 28.4M | 154.9M | 80.1M | 136.2M | 268.3M | 61.5K | |
| Enterprise Value | (21.2M) | 98.6M | 23.3M | 102.6M | 164.9M | 60.7K |
ESSA Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in ESSA Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ESSA Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ESSA Pharma's value.| Shares | Two Sigma Investments Llc | 2024-12-31 | 211.2 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 181.2 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 164.6 K | Citadel Advisors Llc | 2024-12-31 | 159 K | Ubs Group Ag | 2024-12-31 | 95.6 K | Two Sigma Advisers, Llc | 2024-12-31 | 82.6 K | Magnus Financial Group Llc | 2024-12-31 | 55.2 K | Vazirani Asset Management Llc | 2024-12-31 | 50 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 48.8 K | Bvf Inc | 8.7 M | Tang Capital Management Llc | 2024-12-31 | 4.3 M |
ESSA Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (49.12 M) | ||||
| Shares Outstanding | 44.39 M | ||||
| Shares Owned By Insiders | 6.01 % | ||||
| Shares Owned By Institutions | 71.00 % | ||||
| Number Of Shares Shorted | 678.18 K | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 0.60 X | ||||
| EBITDA | (23.5 M) | ||||
| Net Income | (28.54 M) | ||||
| Cash And Equivalents | 174.6 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 329.26 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 43.43 X | ||||
| Book Value Per Share | 2.68 X | ||||
| Cash Flow From Operations | (22.72 M) | ||||
| Short Ratio | 2.81 X | ||||
| Earnings Per Share | (0.69) X | ||||
| Target Price | 11.59 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.6 | ||||
| Market Capitalization | 71.02 M | ||||
| Total Asset | 128.11 M | ||||
| Retained Earnings | (208 M) | ||||
| Working Capital | 124.26 M | ||||
| Current Asset | 10.02 M | ||||
| Current Liabilities | 3.63 M | ||||
| Net Asset | 128.11 M |
About ESSA Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ESSA Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ESSA Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ESSA Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.